Search – University of Copenhagen

Eric Ofosu Kissi

Eric Ofosu Kissi

PhD fellow

  • Solid State Pharmaceutics

    Universitetsparken 2, 2100 København Ø, 13, Building: 13-6-634

    Phone: +45 35 33 17 91

Amorphous systems have been developed as among other strategies to improve the solubility of poorly aqueous soluble crystalline drugs.  In fact, drugs that have poor aqueous solubility are a major challenge in drug development and it has been estimated that about 40% of new chemical entities suffer this fate and do not make it to the development stage. Drugs that are poorly soluble in aqueous medium will show poor solubility in the gastrointestinal tract and will lead to low bioavailability. Therefore, formulating drugs in the amorphous form is seen not only as increasing solubility but also increasing their bioavailability. As interesting as this sounds, amorphous drugs also face a major challenge, recrystallization. Recrystallization is the conversion of disordered molecules in an amorphous form into ordered systems as seen in crystalline forms. This requires that the high energetic amorphous system loses its energy, which gives it its solubility advantage, to the equilibrium state. Recrystallization coupled with the gap in knowledge in the physicochemical properties of amorphous drugs is a bottleneck to the development of amorphous form of drugs both to industry and academia.  Knowledge in the physicochemical properties and in particular physical stability is of outmost importance in developing amorphous drugs into mainstream pharmaceutical products.We are currently focusing on understanding a key parameter in recrystallization of amorphous drugs, their molecular mobility.

ID: 141784051